RBC Capital Maintains Outperform on Ligand Pharmaceuticals, Raises Price Target to $252
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
RBC Capital analyst Douglas Miehm maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperform and raises the price target from $235 to $252.
RBC Capital analyst Douglas Miehm maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperform and raises the price target from $235 to $252.